February 28, 2017
FDA OK’s AstraZeneca’s diabetes drug
US Food and Drug Administration (FDA) has approved AstraZeneca’s once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
February 28, 2017
Novo Nordisk submits NDA for its diabetes drug in Japan
Novo Nordisk has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for semaglutide, a new glucagon-like peptide-1 (GLP-1) analogue administrated once-weekly, for the treatment of adults with type 2 diabetes.
February 28, 2017
Oxford BioMedica welcomes Stuart Paynter to its board
Oxford BioMedica, a leading gene and cell therapy group, announces that Stuart Paynter will join Oxford BioMedica as Chief Financial Officer to succeed Tim Watts, who has decided to retire from full time executive roles.
February 27, 2017
J&J buys Abbott Medical Optics for $4,3 billion
Johnson & Johnson has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott for $4.325 billion
February 27, 2017
Matinas BioPharma joins NYSE
Matinas BioPharma Holdings has been approved for listing on the New York stock exchange, and will be trading under the symbol “MTNB” starting from March 2, 2017.
February 27, 2017
Former Pfizer, current Centrexion CEO joins Israel’s Pharma Two B’s board of directors after leading $30M worth third financing round
Former Pfizer CEO and chairman Jeff Kindler will be joining privately held Israel’s drugmaker Pharma Two B’s board of directors, as the company completed its third round of financing, raising $30 million, with Israel Biotech Fund (IBF) leading the procedure. Jeff Kindler is a member of Israel Biotech Fund’s Venture Advisory Team.
February 27, 2017
Allergan’s IR vice president leaves
Allergan’s Vice President of Investor Relations, Lisa DeFrancesco, has resign after being nearly 8 years of leading the Investor Relations of the company.
February 27, 2017
argenx and Shire extend partnership to fight rare diseases
Argenx and Shire have extended their strategic partnership from 2014 to advance the discovery and development of novel human therapeutic antibodies for diverse rare and unmet diseases for a further year until May 30, 2018.
February 27, 2017
Valeant’s Bausch + Lomb and Nicox reapply for their eye drug
Valeant Pharmaceuticals`s subsidiary, Bausch + Lomb, and Nicox have resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for latanoprostene bunod ophthalmic solution, 0.024%.
February 27, 2017
Verona puts COPD candidate RPL544 in focus for 2017, NASDAQ in four months?
According to Verona Pharma’s CEO, Dr. Jan-Anders Karlsson, the highlights of 2016 were encouraging clinical data for RPL554, additional financing from “a very experienced syndicate” of investors, and further strengthening of the company’s Board and executive team.